GSK (LON:GSK) Stock Price Passes Above 200 Day Moving Average - What's Next?

GSK plc (LON:GSK - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,448.19 ($18.53) and traded as high as GBX 1,478.50 ($18.91). GSK shares last traded at GBX 1,467.50 ($18.77), with a volume of 16,677,213 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GSK. Berenberg Bank decreased their price objective on GSK from GBX 1,820 ($23.28) to GBX 1,600 ($20.47) and set a "buy" rating for the company in a report on Friday, November 29th. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of GBX 1,805.83 ($23.10).

GSK Price Performance

The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market capitalization of £60.18 billion, a price-to-earnings ratio of 23.96, a PEG ratio of 1.24 and a beta of 0.31. The company has a 50 day moving average of GBX 1,398.01 and a 200 day moving average of GBX 1,447.27.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Remove Ads

Insider Buying and Selling

In other news, insider Jonathan Symonds purchased 1,500 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were purchased at an average price of GBX 1,315 ($16.82) per share, for a total transaction of £19,725 ($25,233.47). Also, insider Emma Walmsley sold 38,459 shares of GSK stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.14), for a total value of £545,348.62 ($697,644.39). 1.61% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.